Last week @fda sends out clarification on who can and cannot compound #glp1 like #tirzeaptide and #semaglutide and this week ProRx 503b shuts down GLP 1 compounding while @martymakary is photographed holding bootleg # Restoring Balance: What the FDA's Peptide Announcement Could Mean for Patient Access and Safety Empower Pharmacy Peptides: Legal and Regulatory Risks 503A Compounding Pharmacies Must Understand The FDA scheduled a hearing on peptides and the implications could be significant for prescribers and FDA Puts BPC 157, TB 500, and 5 Other Peptides Under the Microscope: What Prescribers Need to Know About the 503A Review Lengea